Core Insights - The National Medical Insurance Drug List for 2025 includes 11 anti-tumor products from Heng Rui Medicine, with 5 innovative drugs newly added to the national insurance directory, enhancing accessibility for patients [1] - Heng Rui's oncology division has developed a differentiated product matrix covering various high-incidence tumors, including immunotherapy and targeted therapy [1][5] Group 1: New Drug Inclusion - Five innovative drugs newly included in the insurance directory are: - Injection of Rukang Trastuzumab (Aivida®) - Injection of Phronolapitan Palonosetron (Ruitanning®) - Malic Acid Famitinib Capsules (Aibite®) - Acetate Abiraterone Tablets (II) (Airiji®) - Liposomal Irinotecan Injection (II) (Yueyouli®) [1][2] - These drugs address long-standing treatment gaps in various cancers, providing improved accessibility and efficacy for patients [1][2] Group 2: Expanded Indications - Three existing drugs in the insurance directory have expanded indications: - Fluorouracil Capsules (Airiyi®) now includes treatment options for breast cancer patients with specific genetic markers - Apatinib Tablets (Aitan®) have new indications for combination therapy - Injection of Carrelizumab (Airika®) is now indicated for recurrent/metastatic cervical cancer [3][4] Group 3: Long-term Drug Continuity - Three key products have successfully renewed their insurance coverage, ensuring continuous access for patients: - Pyrotinib Tablets (Airini®) for HER2-positive breast cancer - Hecoriparib Ethanolamine Tablets (Hengqu®) for immune thrombocytopenia and severe aplastic anemia - Sulfapeginterferon Injection (Aido®) for reducing infection risk in chemotherapy patients [4][5] Group 4: Overall Coverage - Out of 16 innovative drugs launched by Heng Rui, 14 have been included in the national insurance directory, achieving near-complete coverage of innovative results [5] - The company aims to continue focusing on patient needs while expanding its technological platforms and diverse pipeline to meet unmet clinical demands [5]